Last reviewed · How we verify
Atazanavir + 2 NRTIs
Atazanavir inhibits HIV protease to prevent viral replication, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcription of viral RNA.
Atazanavir inhibits HIV protease to prevent viral replication, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcription of viral RNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.
At a glance
| Generic name | Atazanavir + 2 NRTIs |
|---|---|
| Also known as | Reyataz |
| Sponsor | Bristol-Myers Squibb |
| Drug class | Protease inhibitor (PI) + nucleoside reverse transcriptase inhibitors (NRTIs) |
| Target | HIV protease; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Atazanavir is a protease inhibitor that binds to and blocks HIV protease, preventing the cleavage of viral polyproteins necessary for producing mature, infectious viral particles. The two NRTIs work synergistically by inhibiting reverse transcriptase, the enzyme that converts HIV RNA into DNA, thereby blocking an earlier step in viral replication. Together, this triple-drug combination provides potent suppression of HIV replication through complementary mechanisms.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- HIV-1 infection as part of combination antiretroviral therapy
Common side effects
- Hyperbilirubinemia (unconjugated)
- Jaundice
- Nausea
- Diarrhea
- Headache
- Rash
- Nephrolithiasis
- PR interval prolongation
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression (PHASE3)
- Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents (PHASE1, PHASE2)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir + 2 NRTIs CI brief — competitive landscape report
- Atazanavir + 2 NRTIs updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI